Cue Biopharma (CUE) Invested Capital (2017 - 2025)
Cue Biopharma (CUE) has disclosed Invested Capital for 9 consecutive years, with $26.4 million as the latest value for Q4 2025.
- Quarterly Invested Capital rose 21.07% to $26.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.4 million through Dec 2025, up 21.07% year-over-year, with the annual reading at $26.4 million for FY2025, 21.07% up from the prior year.
- Invested Capital hit $26.4 million in Q4 2025 for Cue Biopharma, up from $14.7 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $73.7 million in Q4 2022 to a low of $10.0 million in Q1 2025.
- Historically, Invested Capital has averaged $45.4 million across 5 years, with a median of $49.8 million in 2023.
- Biggest five-year swings in Invested Capital: soared 54.01% in 2021 and later crashed 69.87% in 2025.
- Year by year, Invested Capital stood at $65.5 million in 2021, then grew by 12.51% to $73.7 million in 2022, then crashed by 44.24% to $41.1 million in 2023, then tumbled by 46.86% to $21.8 million in 2024, then rose by 21.07% to $26.4 million in 2025.
- Business Quant data shows Invested Capital for CUE at $26.4 million in Q4 2025, $14.7 million in Q3 2025, and $20.6 million in Q2 2025.